{"id":"elliptinium","rwe":[{"pmid":"39395905","year":"2024","title":"Integrated analysis of single-cell RNA-seq and bulk RNA-seq revealed key genes for bone metastasis and chemoresistance in prostate cancer.","finding":"","journal":"Genes & genomics","studyType":"Clinical Study"},{"pmid":"34675254","year":"2021","title":"Potential efficacy of existing drug molecules against severe fever with thrombocytopenia syndrome virus: an in silico study.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"34486940","year":"2022","title":"FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies.","finding":"","journal":"Journal of biomolecular structure & dynamics","studyType":"Clinical Study"},{"pmid":"23700916","year":"2012","title":"Plant-derived anticancer agents - curcumin in cancer prevention and treatment.","finding":"","journal":"Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi","studyType":"Clinical Study"},{"pmid":"23484647","year":"2007","title":"Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development.","finding":"","journal":"Expert opinion on drug discovery","studyType":"Clinical Study"}],"tags":[{"label":"elliptinium","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Mast/stem cell growth factor receptor Kit","category":"target"},{"label":"KIT","category":"gene"},{"label":"FGFR3","category":"gene"},{"label":"PDGFRA","category":"gene"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Indicators and Reagents","category":"pharmacology"},{"label":"Intercalating Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"celiptium","offLabel":[],"synonyms":["elliptinium","celiptium","ellipticine acetomethylate","elliptinium acetate"],"timeline":[],"approvals":[],"brandName":"Celiptium","ecosystem":[],"mechanism":{"target":"Fibroblast growth factor receptor 3, Mast/stem cell growth factor receptor Kit, Platelet-derived growth factor receptor alpha","targets":[{"gene":"KIT","source":"DrugCentral","target":"Mast/stem cell growth factor receptor Kit","protein":"Mast/stem cell growth factor receptor Kit"},{"gene":"FGFR3","source":"DrugCentral","target":"Fibroblast growth factor receptor 3","protein":"Fibroblast growth factor receptor 3"},{"gene":"PDGFRA","source":"DrugCentral","target":"Platelet-derived growth factor receptor alpha","protein":"Platelet-derived growth factor receptor alpha"}],"modality":"Small Molecule","drugClass":"elliptinium","explanation":"Think of it like a traffic light for cells. The Kit receptor is like a green light that tells cells to grow and multiply. Celiptium acts like a red light, stopping the green light from working and slowing down cell growth.","oneSentence":"Celiptium works by blocking the Kit receptor, which helps control cell growth and division.","technicalDetail":"Celiptium exerts its effects by competitively binding to the extracellular domain of the Kit receptor, thereby inhibiting the receptor's autophosphorylation and downstream signaling pathways involved in cell proliferation and survival."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/996","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELLIPTINIUM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:54:10.841370","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:15:09.565149+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"avapritinib","drugSlug":"avapritinib","fdaApproval":"2020-01-09","patentExpiry":"Oct 15, 2034","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"axitinib","drugSlug":"axitinib","fdaApproval":"2012-01-27","patentExpiry":"Jun 14, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bosutinib","drugSlug":"bosutinib","fdaApproval":"2012-09-04","patentExpiry":"Nov 23, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cabozantinib","drugSlug":"cabozantinib","fdaApproval":"2012-11-29","patentExpiry":"Oct 8, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"ceritinib","drugSlug":"ceritinib","fdaApproval":"2014-04-29","patentExpiry":"Nov 20, 2027","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cianidanol","drugSlug":"cianidanol","fdaApproval":"","relationship":"same-target"},{"drugName":"crizotinib","drugSlug":"crizotinib","fdaApproval":"2011-08-26","patentExpiry":"Oct 8, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dasatinib","drugSlug":"dasatinib","fdaApproval":"2006-06-28","patentExpiry":"Sep 28, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"erlotinib","drugSlug":"erlotinib","fdaApproval":"2004-11-18","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"fedratinib","drugSlug":"fedratinib","fdaApproval":"2019-08-16","patentExpiry":"Sep 24, 2039","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"elliptinium","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"avapritinib","brandName":"avapritinib","genericName":"avapritinib","approvalYear":"2020","relationship":"same-target"},{"drugId":"axitinib","brandName":"axitinib","genericName":"axitinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"bosutinib","brandName":"bosutinib","genericName":"bosutinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"cabozantinib","brandName":"cabozantinib","genericName":"cabozantinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"ceritinib","brandName":"ceritinib","genericName":"ceritinib","approvalYear":"2014","relationship":"same-target"},{"drugId":"cianidanol","brandName":"cianidanol","genericName":"cianidanol","approvalYear":"","relationship":"same-target"},{"drugId":"crizotinib","brandName":"crizotinib","genericName":"crizotinib","approvalYear":"2011","relationship":"same-target"},{"drugId":"dasatinib","brandName":"dasatinib","genericName":"dasatinib","approvalYear":"2006","relationship":"same-target"},{"drugId":"erlotinib","brandName":"erlotinib","genericName":"erlotinib","approvalYear":"2004","relationship":"same-target"},{"drugId":"fedratinib","brandName":"fedratinib","genericName":"fedratinib","approvalYear":"2019","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"006100","UNII":"1F1959S062","CHEBI":"CHEBI:135147","INN_ID":"4783","UMLSCUI":"C0115685","ChEMBL_ID":"CHEMBL16699","PUBCHEM_CID":"42723","SECONDARY_CAS_RN":"58337-34-1","MESH_SUPPLEMENTAL_RECORD_UI":"C027767"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":69,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"2024 Dec","pmid":"39395905","title":"Integrated analysis of single-cell RNA-seq and bulk RNA-seq revealed key genes for bone metastasis and chemoresistance in prostate cancer.","journal":"Genes & genomics"},{"date":"2021 Oct 21","pmid":"34675254","title":"Potential efficacy of existing drug molecules against severe fever with thrombocytopenia syndrome virus: an in silico study.","journal":"Scientific reports"},{"date":"2022","pmid":"34486940","title":"FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies.","journal":"Journal of biomolecular structure & dynamics"},{"date":"2012 Oct-Dec","pmid":"23700916","title":"Plant-derived anticancer agents - curcumin in cancer prevention and treatment.","journal":"Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi"},{"date":"2007 Mar","pmid":"23484647","title":"Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development.","journal":"Expert opinion on drug discovery"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Celiptium (Elliptinium) is a small molecule drug targeting the mast/stem cell growth factor receptor Kit. It is classified as an elliptinium, but its commercial status and approved indications are unknown. The mechanism of action involves inhibiting the Kit receptor, which is involved in cell growth and proliferation. Further information on its safety, pharmacokinetics, and commercial status is not available.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:15:09.565149+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}